Conclusions
TNF-based ILP is very successful as a treatment to achieve limb salvage in the management of advanced, multiple, or drug-resistant extremity tumors. TNF-based ILP is now performed in 30 cancer centers in Europe. TNF-based antivascular therapy for cancer is here to stay, and its potential needs to be studied further [7].
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lienard D, Ewalenko P, Delmotte JJ, et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:50–62.
Eggermont AMM, Schraffordt Koops H, Klausner JM, et al.: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 1996, 224:756–765.
De Wilt JHW, ten Hagen TLM, de Boeck G, et al.: Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000, 82:1000–1003.
Ruegg C, Yilmaz A, Bieler G, et al.: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFNgamma. Nat Med 1998, 4:408–414.
Alexander HR Jr, Bartlett DL, Libutti SK, et al.: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998, 16:1479–1489.
Ten Hagen TL, Van Der Veen AH, Nooijen PT, et al.: Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000, 87:829–837.
Ten Hagen TLM, Lejeune FJ, Eggermont AMM: TNF is here to stay—revisited. Trends Immunol 2001, 22:127–129.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eggermont, A.M.M., Hagen, T.L.M.t. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: Ten years of successful antivascular therapy. Curr Oncol Rep 5, 79–80 (2003). https://doi.org/10.1007/s11912-003-0091-x
Issue Date:
DOI: https://doi.org/10.1007/s11912-003-0091-x